These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 16557202)

  • 1. PET and PET/CT studies of tumor tissue oxygenation.
    Krause BJ; Beck R; Souvatzoglou M; Piert M
    Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):28-43. PubMed ID: 16557202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET/CT for the staging and follow-up of patients with malignancies.
    Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
    Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET monitoring of therapy response in head and neck squamous cell carcinoma.
    Schöder H; Fury M; Lee N; Kraus D
    J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
    Kasamon YL; Jones RJ; Wahl RL
    J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
    Schmidt GP; Kramer H; Reiser MF; Glaser C
    Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography.
    Aboagye EO; Kelson AB; Tracy M; Workman P
    Anticancer Drug Des; 1998 Sep; 13(6):703-30. PubMed ID: 9755726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
    Metser U; Even-Sapir E
    Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing tumor response to therapy.
    Weber WA
    J Nucl Med; 2009 May; 50 Suppl 1():1S-10S. PubMed ID: 19380403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular PET/CT imaging-guided radiation therapy treatment planning.
    Zaidi H; Vees H; Wissmeyer M
    Acad Radiol; 2009 Sep; 16(9):1108-33. PubMed ID: 19427800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
    Krause BJ; Herrmann K; Wieder H; zum Büschenfelde CM
    J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring cancer treatment with PET/CT: does it make a difference?
    Weber WA; Figlin R
    J Nucl Med; 2007 Jan; 48 Suppl 1():36S-44S. PubMed ID: 17204719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging to optimally stage lung cancer: conventional modalities and PET/CT.
    Truong MT; Munden RF; Movsas B
    J Am Coll Radiol; 2004 Dec; 1(12):957-64. PubMed ID: 17411738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography.
    Kuehl H; Rosenbaum-Krumme S; Veit-Haibach P; Stergar H; Forsting M; Bockisch A; Antoch G
    Nucl Med Commun; 2008 Jul; 29(7):599-606. PubMed ID: 18528181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated PET/CT and cancer imaging.
    De Wever W; Coolen J; Verschakelen JA
    JBR-BTR; 2009; 92(1):13-9. PubMed ID: 19358480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries.
    Schwarz JK; Grigsby PW; Dehdashti F; Delbeke D
    J Nucl Med; 2009 May; 50 Suppl 1():64S-73S. PubMed ID: 19380409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of PET/CT in the development of novel anticancer drugs.
    Boss DS; Olmos RV; Sinaasappel M; Beijnen JH; Schellens JH
    Oncologist; 2008 Jan; 13(1):25-38. PubMed ID: 18245010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for cancer with PET and PET/CT: potential and limitations.
    Schöder H; Gönen M
    J Nucl Med; 2007 Jan; 48 Suppl 1():4S-18S. PubMed ID: 17204716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tracers in oncology - preclinical and clinical evaluation].
    Krause BJ; Schwarzenböck S; Schwaiger M
    Nuklearmedizin; 2010; 49 Suppl 1():S41-5. PubMed ID: 21152689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
    Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
    De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
    J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.